ELI LILLY AND COMPANY |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 751.1 EUR | -0.42% |
|
+0.70% | +42.25% |
| 05-30 | Danish Government Implements Stricter Subsidy Rules for Diabetes Drugs | MT |
| 05-30 | Wegovy maker Novo Nordisk sues nine spas, clinics and pharmacies over copycat drugs | RE |
| Sales 2024 * | 42.98B 39.63B 58.57B | Sales 2025 * | 52.62B 48.52B 71.7B | Capitalization | 739B 681B 1,006B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 11B 16.26B | Net income 2025 * | 16.55B 15.26B 22.56B | EV / Sales 2024 * | 17.6 x |
| Net Debt 2024 * | 18.07B 16.66B 24.62B | Net Debt 2025 * | 15B 13.83B 20.44B | EV / Sales 2025 * | 14.3 x |
| P/E ratio 2024 * |
61.4
x | P/E ratio 2025 * |
44.2
x | Employees | - |
| Yield 2024 * |
0.63% | Yield 2025 * |
0.73% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 week | +0.70% | ||
| Current month | +2.71% | ||
| 1 month | +2.71% | ||
| 3 months | +7.53% | ||
| 6 months | +37.69% | ||
| Current year | +42.25% |
1 week
730.70
755.50
1 month
679.00755.50
3 years
160.85755.50
5 years
94.81755.50
10 years
43.21755.50
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 95-12-31 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 00-12-31 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 21-01-24 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 09-03-31 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 04-12-31 |
| Date | Price | Change |
|---|---|---|
| 24-05-31 | 751.1 | -0.42% |
| 24-05-30 | 754.3 | +0.80% |
| 24-05-29 | 748.3 | +1.45% |
| 24-05-28 | 737.6 | -1.50% |
| 24-05-27 | 748.8 | +0.39% |
Delayed Quote Börse Stuttgart, May 31, 2024 at 03:22 pm
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- LLY Stock
- LLY Stock
